Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses

A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer Therapy

(2014) Dong-Sup Chung et al.   Journal of Immunology Research

Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas

(2013) I Sakamaki et al.   LEUKEMIA

Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts

(2013) Masasuke Ohno et al.   Journal for ImmunoTherapy of Cancer

Lenalidomide enhances anti-myeloma cellular immunity

(2012) Katarina Luptakova et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma

(2012) Richard A. Morgan et al.   HUMAN GENE THERAPY

Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions

(2012) Kevin J. Curran et al.   JOURNAL OF GENE MEDICINE

A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806)

(2012) Brian M. Alexander et al.   JOURNAL OF NEURO-ONCOLOGY

Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma

(2011) Pierre Giglio et al.   CANCER

Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen

(2010) Masasuke Ohno et al.   CANCER SCIENCE

Immunotherapy Approaches for Malignant Glioma From 2007 to 2009

(2010) Laura A. Johnson et al.   Current Neurology and Neuroscience Reports

Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma

(2010) M.-d.-M. Inda et al.   GENES & DEVELOPMENT

Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer

(2010) Marc Cartellieri et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

(2009) A. G. Ramsay et al.   BLOOD

Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells

(2009) Irina Idler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

(2008) Christine Galustian et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

(2008) Ling Lu et al.   MICROVASCULAR RESEARCH

Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells

(2008) Khalid Al-Nedawi et al.   NATURE CELL BIOLOGY